Replies to post #42984 on *** MICK, $Pistol Pete$ & FRIENDS STOCK PICKS

[$Pistol Pete$]

$MFST The Time Machine Program Science FDA cleared MFST

[$Pistol Pete$]

$PMCB PharmaCyte Biotech to Hold Shareholder Call PMCB





LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Chief Executive Officer Kenneth L. Waggoner will conduct a shareholder call on Wednesday, November 1, 2017, commencing at 4:30 p.m. EDT.

PharmaCyte to hold shareholder update call.
Tweet this
PharmaCyte will provide the latest information about its preparations for the submission of an Investigational New Drug Application (IND) for its planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC), the work being done to get ready for the trial and a brief update on PharmaCyte’s diabetes program. PharmaCyte will also respond to written questions. Shareholders and analysts are requested to submit questions they have about PharmaCyte’s clinical development program via email to [e-mail]. Mr. Waggoner will respond to as many of the questions as possible in the time permitted for the call.

Date: November 1, 2017
Time: 4:30 p.m. EDT
Telephone Number: [phone]
Access Code: 195864
Once the call has been completed, an audio replay will be available to the public. PharmaCyte will provide a telephone number and access code to listen to the recorded call.

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

Contacts
PharmaCyte Biotech, Inc.
Investor Relations:
Dr. Gerald W. Crabtree, 917.595.2856
[e-mail]
http://www.businesswire.com/news/home/20171020005200/en/PharmaCyte-Biotech-Hold-Shareholder-Call

[$Pistol Pete$]

$LXGTF Daily and Weekly Charts

[$Pistol Pete$]

Good evening MICK

[$Pistol Pete$]

Morning MICK

[$Pistol Pete$]

$RAD Daily and Weekly Chart

[$Pistol Pete$]

$PMCB Daily and Weekly Chart

[$Pistol Pete$]

Good Morning MICK

[mick]

Stock Market News
Top Company News of the Day

[$Pistol Pete$]

$MNKD Major News

MannKind +8% as FDA clears risk hurdles for Afrezza

https://seekingalpha.com/news/3348257-mannkind-plus-8-percent-fda-clears-risk-hurdles-afrezzaMannKind +8% as FDA clears risk hurdles for Afrezza
Seeking Alpha - 30m ago


MannKind (NASDAQ:MNKD) is up 8.1% after hours following a letter from the FDA saying that the company's Afrezza inhalation treatment no longer needs a Risk Evaluation and Mitigation Strategy.MannKind +8% as FDA clears risk hurdles for Afrezza
Seeking Alpha - 30m ago


MannKind (NASDAQ:MNKD) is up 8.1% after hours following a letter from the FDA saying that the company's Afrezza inhalation treatment no longer needs a Risk Evaluation and Mitigation Strategy.

[$Pistol Pete$]

$MEDT is a good one to play during this Summer time

[$Pistol Pete$]

$MNKD Life changing Afrezza - Listen to what Diabetes experts say MNKD

[$Pistol Pete$]

$MNKD Daily and Weekly Chart

[$Pistol Pete$]

$RAD Rite Aid poised to sell its first cannabis-derived drug RAD

http://money.cnn.com/2018/06/27/news/companies/epidiolex-gw-cannabis/index.html


Go $RAD

[$Pistol Pete$]

$MNKD Daily and Weekly Chart

[$Pistol Pete$]

$PMCB Daily and Weekly Chart

[$Pistol Pete$]

$PMCB PharmaCyte Biotech Successfully Completes Another FDA Required Study Necessary for Submitting Investigational New Drug Application PMCB

https://www.nasdaq.com/press-release/pharmacyte-biotech-successfully-completes-another-fda-required-study-necessary-for-submitting-20180614-00515



Go $PMCB

[mick]

$ACRL---$500-K,$2MIL.,$5MIL.[BUY-IN-40%]PREFERRED B CONFIDENTIAL 03-25-2019 UPDATE FROM CEO
excerpt-#1
With a proven reserve pegged at a more realistic $1 billion dollars,
the contribution to the market value of the company would be approximately $1 dollar per share.

excerpt-#2; Starting with an assumption that the ACRL
common shares could end up valued up to $1.00 per share

because of the proven reserve confirmation,
the investor upside is as follows.

on guard---raise sword --- $5mil. buys 40% interest in $ACRL

hi there , good morning

alert on this one


We could have big time winner here --- ALL SHOULD READ

i missed that confidential ceo write, reread and $500-k deal, $2mil, $5mil. buys 40% of the company.

03-25-2019

==========================================================

'Atacama Resources International, Inc. (ACRL)'

Intro One of Twenty---$ACRL---B PREFERRED 6MOS HOLD WITH AH GOLD FIND and Interest Payment

https://drive.google.com/file/d/1cdtRFtx1fSmjvmatx9DzkfCLXC3_kMjd/view

good morning, the 03-25-2019 confidential write said $5 mil makes 40% deal

buyout by ceo $ACRL

is dat about $1 per share ?????

Atacama Resources International, Inc. (ACRL)'

https://investorshub.advfn.com/Atacama-Resources-International-Inc-ACRL-31214/

==========================================================

$ACRL/ PROVEN MINING EVALUATION/ADDING LINKS/ PRECIOUS METALS & MINERAL MINING/ ATACAMA RESOURCES INTERNATIONAL some profiling
https://acrlintl.com/mining

$ACRL Company Links Listed Below. Do your DD!
1. Atacama Resources International: https://acrlintl.com/
2. Good2Drive: http://good2drive.com/
3. Fit4Duty http://fit4dutynow.net/
4. Google Play App: https://play.google.com/store/apps/details?id=ca.mgisinc.good2drive …
5. Twitter: https://twitter.com/acrlintl_MINING / @acrlintl_MINING

https://twitter.com/search?f=tweets&vertical=default&q=Good2Drive

==================================================================

We are Atacama Resources International Ltd a subsidiary of Atacama Resources International Inc.
Dedicated to the exploration and development of
gold,
diamonds,
cobalt and
graphite resources,
our goal is to become an important North American source for these precious metals and minerals.

MINERALS & LOCATIONS
Success in this business depends on market demand,
location,
cost minimization,
experienced operators and dependable funding.

The good news is demand for all the minerals and precious metals on
our exploration sites is expected to rise.

We have multiple claims on 4460 acres in the Kirkland Lake and
other areas of mineral-rich northern Ontario.

These sites are easily accessible to existing roads and rail,
close to mining communities,
and near mining exploration,
development and
refining operations.

In short – we are well-positioned in a proven mining area with anticipated cost-efficient operations.

A team of mining and business experts has been assembled to manage
and operate the projects on our claims.

We have engaged the services of Canadian Exploration Services (CXS),
a leading and highly respected provider of exploration services,
as a key member of our team.

We have a strategy for providing on-going revenue and cash flow
during the exploration and development phases of our projects.

Adequate funding that is not fully dependent on costly financing
is unique in our industry and is made possible
by our parent company, Atacama Resources International, Inc. (ACRL OTCQB).

ACRL owns another company, GOOD2DRIVE, a high-tech business that
is positioned to produce cash flow and funding for the mining operations.

CXS MANAGEMENT TEAM
Canadian Exploration Services (CXS) manages our mining operations.
A leading provider of exploration geophysics,
exploration services
and construction services, CXS operates a modern fleet of heavy equipment,
including drilling rigs,
excavators,
backhoes,
bulldozers,
road graders,
dump trucks rock trucks,
and other heavy machinery.

They also offer complete geophysical survey design, implementation, interpretation and reporting services.

Technical Services / Construction:

43-101 report writing

Mining claim Geo-referencing to MNDM standards or better

Differential GPS services with accuracy of up to 2cm possible

Exploration Plans and Permits preparation and submission

First Nation consultation

Complete exploration project management

Mining claim staking in Ontario and Quebec

Line cutting services

Channel sampling

Hydraulic pressure washing

Soil sampling: MMI, humus, till etc. sampling and reporting

Prospecting with full reports

Mining claim inspections

Mining hazard inspections and remediation to MNDM Provincial Standard

ct supervision

Drill road and pad construction

Helicopter pad construction

Bush road construction including culvert & bridge installation

Summer and winter and maintenance

Core sawing in field or in our core saw room

Core shack rental in Larder Lake or field core shack installation/rental

Sonic drilling for tailings sampling or soil sampling at depth

Portable Diamond Drilling under 150kg.

Forestry consulting

Work permit applications for Ontario (culverts, roads etc.)

Water sampling

Geophysics



[-chart]investorshub.advfn.com/uimage/uploads/2017/8/2/tyjltScreen_Shot_2017-08-02_at_1.59.39_PM.png[/chart]



https://acrlintl.com/good2drive
A SMART APP FOR SMART DRIVERS.
Good2Drive is a smartphone app that measures your cognitive ability through a 60 to 90 second test.

Once you take the test,
it analyzes the results and tells you if you’re good to drive or not.

Even if you haven’t had a drink, the test will tell you if are too tired to be behind the wheel.






FIT4DUTY
https://acrlintl.com/good2drive-1/
A SMART APP FOR SMART EMPLOYERS.
Fit4Duty has been specifically designed to help some of the most dangerous industries keep their employees,
equipment,
and customers safe.

Being aware is the first step to a safe workplace so let's stop an accident before it can even happen.

GOLD/ COBALT/ COPPER/ DIAMONDS/ GRAPHITE/ IRON ORE

================================================

#3A/ part ten/ $ACRL/ PRECIOUS METALS & MINERAL MINING/ ATACAMA RESOURCES INTERNATIONAL some profiling
https://acrlintl.com/mining




[-chart]investorshub.advfn.com/uimage/uploads/2017/8/2/tyjltScreen_Shot_2017-08-02_at_1.59.39_PM.png[/chart]

https://acrlintl.com/good2drive
A SMART APP FOR SMART DRIVERS.
Good2Drive is a smartphone app that measures your cognitive ability through a 60 to 90 second test.

Once you take the test, it analyzes the results and tells you if
you’re good to drive or not.

Even if you haven’t had a drink, the test will tell you if are
too tired to be behind the wheel.

[chart]
static1.squarespace.com/static/58b5961486e6c0717e9be46f/t/58d6b65417bffcffb800f754/1512765727107/AdobeStock_96529251_WM.jpeg?format=1500w[/chart]

[-chart]static1.squarespace.com/static/58b5961486e6c0717e9be46f/t/58d6b65417bffcffb800f754/1512765727107/AdobeStock_96529251_WM.jpeg?format=1500w[/chart]

FIT4DUTY
https://acrlintl.com/good2drive-1/
A SMART APP FOR SMART EMPLOYERS.
Fit4Duty has been specifically designed to help some of the most dangerous industries keep their employees,
equipment,
and customers safe.

Being aware is the first step to a safe workplace so let's stop an accident before it can even happen.


=========================================================

GOLD/


COBALT/


COPPER/


DIAMONDS/


GRAPHITE/


IRON ORE/



========================================================

GOLD/
[-chart]static1.squarespace.com/static/58b5961486e6c0717e9be46f/t/58d6927bf7e0ab027a05c1f7/1490457217358/AdobeStock_73883937.jpeg?format=500w[/chart]

COBALT/
[-chart]static1.squarespace.com/static/58b5961486e6c0717e9be46f/t/58d68fd5bf629acc7bcdf894/1490456559985/AdobeStock_51615139_WM.jpeg?format=500w[/chart]

COPPER/
[-chart]static1.squarespace.com/static/58b5961486e6c0717e9be46f/t/58d690a05016e1c3ee5ef26d/1490456746050/AdobeStock_98809393.jpeg?format=500w[/chart]

DIAMONDS/
[-chart]static1.squarespace.com/static/58b5961486e6c0717e9be46f/t/58d690fed482e9953904086d/1490456848404/AdobeStock_68401022.jpeg?format=500w[/chart]

GRAPHITE/
[-chart]static1.squarespace.com/static/58b5961486e6c0717e9be46f/t/58d7c0701b631bd2a7096bdf/1490535429339/?format=300w[/chart]

IRON ORE/
[-chart]static1.squarespace.com/static/58b5961486e6c0717e9be46f/t/58d7c08dff7c50b17287a665/1490535441167/?format=300w[/chart]


=======================================================

MINING EVALUATION/

READING THIS NOW/'Atacama Resources International, Inc. (ACRL)'

Very interesting rambling.

https://acrlintl.com/blog/2018/11/23/ceo-ramblings-november-23-2018

The investment required to fully confirm the
Atacama 1, 2 and 3 proven reserves has been fully budgeted on
a project management basis and equals $5 million dollars.

Required costs are substantiated for audit and review.

Our investment initiative must focus on a $5 million capital raise
over the next year with a first tranche of at least $1 million dollars immediately.

The upside for the confirmation of gold ‘proven reserves’ for the

Atacama 1, 2 and 3 holdings
is almost too large to be believable.

An analysis of the ACRL position,
similar to the KLG analysis for its new shaft,
would yield a proven reserve in the $5 billion dollar range.

With a proven reserve pegged at a more realistic $1 billion dollars,
the contribution to the market value of the company would be approximately $1 dollar per share.

Starting with an assumption that the ACRL common shares could end up

valued up to $1.00 per share

because of the proven reserve confirmation,
the investor upside is as follows.

The investment offered with this capital raise is to sell the B shares

at the equivalent of one cent per common share with a six-month hold.

The investor, under even a worst-case scenario, should see
a significant return in his ACRL investment

========================================================

[/b[

[TheSerb]

$RXMD - HUGE NEWS OUT! December performance brings 2019 sales to a close at $32.25 million (up 54% year-over-year) on more than 450,000 prescriptions filled (up 50% year-over-year), with Family Physicians Rx (FPRX) contributing from June 1 through December 31, 2019.
In addition, the Company has already begun the audit of 2019 financial data for all consolidated operations. The process associated with uplisting Progressive Care ( RXMD
Loading...
Loading...
) shares onto a major US-listed exchange in 2020 continues to move forward. Audited financials will be submitted on or before March 31. The Company will then move to formally file Form S-1 with the US Securities and Exchange Commission during April before submitting an application for uplisting shares to either the Nasdaq or NYSE.